1. Preclinical Ischemia Model Systems --;1. Primary Cultures for Testing Neuroprotective Drugs --;2. Modeling Neurodegeneration and Neuroprotection in Hippocampal Slices --;3. Stroke Models for Preclinical Trials of Neuroprotective Agents --;4. Animal Models of Ischemia --;5. Head Trauma Model Systems --;2. Neuroprotective Approaches in Stroke and Head Trauma --;6. Excitotoxicity, Cerebral Ischemia, and Neuroprotection by Competitive NMDA Receptor Antagonists --;7. Excitatory Amino Acids and Neuroprotection --;8. Calcium Channel Blockers and Neuroprotection --;9. Self-Defense of the Brain: Adenosinergic Strategies in Neurodegeneration --;10. Gangliosides: New Generation of Neuroprotective Agents --;11. Lazaroids: Novel Cerebroprotective Antioxidants --;12. Membrane-Derived Lipid Second Messengers as Targets for Neuroprotection: Platelet-Activating Factor --;13. Protection Against Oxidative Damage to CNS by?-Phenyl-tert-butyl Nitrone and Other Spin-Trapping Agents: A Novel Series of Nonlipid Free Radical Scavengers --;14. Insulin, Hypoglycemia, and Ischemic Neuroprotection --;15. Temperature Modulation of Neuronal Injury --;3. Clinical Endpoints for Neuroprotective Drugs --;16. Clinical Trial Issues in Stroke Therapy --;17. Excitotoxicity and Neurodegenerative Disorders.
In the 1980s the revolutions of molecular biology have been applied aggressively to the neurosciences with molecular cloning for neuropeptide precursors, many important neurochemical en- zymes, and receptors for numerous transmitters.